Overview of Poster Presentation

A. Cirrhosis, Fibrosis, Tumors

A 01. NONINVASIVE DETECTION OF LIVER FIBROSIS
Aiglová K

A 02. LARGE PRIMARY GLOMUS TUMOR OF THE LIVER IN AN IRANIAN BALOCH WOMAN
Amoueian S, Tayyebi Meibodi N, Attaranzadeh A, Montazer M, Tavoosi H, Ekramifar VR

A 03. SERUM RETINOL BINDING PROTEIN 4 (RBP-4) IS A UNIQUE SURROGATE MARKER OF END STAGE LIVER DISEASE WITH COMPLICATIONS. A PILOT CLINICAL TRIAL
Basu P, Krishnaswamy NV, Korapati R, Shah NJ, Tang CC, Brown R

A 04. ASCITIC FLUID. IS IT A POSSIBLE ORIGIN FOR HYPERFIBRINOLYSIS IN ADVANCED HEPATITIS-C PATIENTS ?
Elnaggar Y, Zuar M

A 05. IMPORTANCE OF NUTRITIONAL STATE AND METABOLIC RATE TO SURVIVAL OF PATIENTS UNDERGOING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
Fajfrová J, Šafka V, Hůlek P, Fejfar T, Jirkovský V, Pavlík V, Hlúbik P

A 06. THE VALUE OF TRANSABDOMINAL ULTRASOUND (US) IN THE DIAGNOSIS OF EXTRAHEPATIC CHOLANGIOCARCINOMA: A COMPARATIVE STUDY WITH MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP)
Gologan E, Achitei D, Bocan R, Balan G

A 07. INFLUENCE OF BACTERIAL INFECTION ON APPEARANCE AND PROGNOSIS OF BLEEDING IN PATIENTS WITH LIVER CIRRHOSIS
Husová L, Lata J, Senkyřík M, Juránková J, Husa P

A 08. DETERMINING RESECTABILITY OF HEPATOCELLULAR CARCINOMA BY MEANS OF LAPAROSCOPIC ULTRASONOGRAPHY
Christodoulidis G, Battyanyi I, Tepetes K

A 09. TRANSARTERIAL CHEMOEMBOLIZATION (TACE) OF HEPATIC METASTASIS FROM NEUROENDOCRINE TUMORS
Iribarren A, Martos M, Orcolaga R, Castiella A, Arriola JA, Alvarez-Coca M, Muro N, Elosegui E, Utrilla E

A 10. DO WE HAVE MORE PREDICTIVE HCC BIOMARKERS ? USEFULNESS OF NEW GENERATION OF HCC BIOMARKERS IN IMMUNE COMPLEXES WITH IMMUNE GLOBULINS OF THE IgM CLASS
Krygier R, Stefaniuk P, Dusza M, Jabłonowska M, Mikula T, Dabrowska M, Cianciara J, Wiercinska-Drapalo A

A 11. COMPARATIVE DIAGNOSTIC VALUE OF CONTRAST-ENHANCED ULTRASONOGRAPHY, MAGNETIC RESONANCE IMAGING AND TOMOGRAPHY IN FOCAL LIVER LESIONS
Martos M, Iribarren A, Poch M, Mugica G, Garmendia G, Arriola JA, Castiella A, Muro N, Elosegui E, Utrilla E

A 12. MANAGEMENT OF ASCITES
Sanganalmath P, Warburton R, Douds A

A 13. HEPATOCELLULAR CARCINOMA IN SLOVAKIA: A TERTIARY REFERRAL CENTRE EXPERIENCE
Skladany L, Adamcova S, Balaz J, Pritzova E, Okapec S, Hampl F

B. Clinical Hepatology

B 01. LIVER IRON CONCENTRATION QUANTIFICATION BY MRI. IS THE RENNES UNIVERSITY PROTOCOL ACCURATE ENOUGH FOR CLINICAL PRACTICE?
Castiella A, Zapata E, Alústiza JM, Emparanza JI, Costero B, Diez MI, Otazua P, Fernandez J, Zubiaurre L, Arriola JA, Alzate LF, Múgica F, Elósegui E, Cabriada JL, Utrilla E

B 02. DIFFERENCES BETWEEN HEMOCHROMATOSIS PATIENTS WITH HFE C282Y HOMOZYGOSITY AND OTHER HFE GENOTYPES IN THE BASQUE COUNTRY
Castiella A, Zapata E, Otazua P, de Juan MD, Fernandez J, Zubiaurre L, Arriola J, Mugica F, Elosegui E, Alzate L, Cabriada J, Utrilla E

B 03. IMPACT OF DIETING AND REDUCTION OF WEIGHT LOSS ON LIPIDS SERUM LEVEL
Fajfrová J, Pavlík V, Husárová M, Vosečková A, Bednarčík P, Halajčuk T, Střítecká H, Hlúbik P

B 04. INTRAHEPATIC CHOLESTASIS AND REPORT OF TWO RARE AND INTERESTING CASES
Farhoudi M, Mokhtarifar A, Mirsadrai S, Farhoudi M

B 05. ADVANCED SURGICAL TREATMENT STRATEGIES FOR HYDATID LIVER DISEASE: A SINGLE INSTITUTE EXPERIENCE
Christodoulidis G, Spyridakis M, Balogiannis I, Dimas D, Tepetes K

B 06. AMOEBIC LIVER ABSCESSES. THE EXPERIENCE AT OUR HOSPITAL
Martos M, Iribarren A, Iribarren JA, Castiella A, Arriola JA, Alvarez-Coca M, Muro N, Elosegui E, Utrilla E

B 07. CLINICAL FEATURES AND THERAPEUTIC STRATEGY FOR TAMOXIFEN INDUCED NONALCOHOLIC STEATOHEPATITIS (NASH)
Saibara T, Toda K, Okamoto N, Hirose A, Nozaki Y, Takahashi M, Ono M, Iwasaki S

B 08. BILIARY SLUDGE IN LIVER DISEASES
Turcanu A

C. Experimental Hepatology

C 01. HISTOLOGICAL AND IMMUNOHISTOCHEMICAL EFFECTS OF THE POSTULATED PROTECTIVE AND THERAPEUTIC EFFECTS OF PENTOXIFYLLINE ON THIOACETAMIDE INDUCED HEPATIC FIBROSIS IN ALBINO RATS
Ahmed MS, Shaalan A

C 02. CAN AMINOPHYLLINE INFLUENCE HEPATOTOXICITY INDUCED BY ACETAMINOPHEN IN VITRO?
Al-Dury S, Šembera Š, Kučera O, Roušar T, Staňková P, Lotková H, Červinková Z

C 03. HEME OXYGENASE-1 AND NITRIC OXIDE SYNTHASE-2 IN HEPATOTOXICITY AND HEPATOPROTECTION MODEL IN RATS: mRNA GENE EXPRESSION MODULATORY EFFECTS OF HEMIN AND ZINC-PROTOPORPHYRIN IX
Černý D, Lekic N, Farghali H, Hořínek A, Váňová K, Muchová L

C 04. PRAVASTATIN MODULATES DIFFERENTIALLY LIVER CHOLESTEROL HOMEOSTASIS IN CONTROL AND BILE DUCT OBSTRUCTED RATS
Kolouchová G, Hiršová P, Brčáková E, Cermanová J, Fuksa L, Lotková H, Mokrý J, Mičuda S

C 05. RAT LIVER AFFECTED BY NON-ALCOHOLIC STEATOSIS IS MORE SUSCEPTIBLE TO ACUTE TOXIC EFFECT OF ACETAMINOPHEN
Kučera O, Staňková P, Lotková H, Roušar T, Garnol T, Červinková Z

C 06. DIFFERENTIAL SELECTED GENES RESPONSE TO D-GALACTOSAMINE-LIPOPOLYSACCHARIDE HEPATOTOXICITY IN RAT
Lekić N, Černý D, Hořínek A, Farghali H

C 07. THE EFFECT OF FLUVASTATIN ON THE PROGRESSION OF CHOLESTATIC LIVER INJURY INDUCED BY BILE DUCT LIGATION IN RATS
Lotková H, Staňková P, Roušar T, Mičuda S, Brčáková E, Kolouchová G, Kohoutek L, Červinková Z

C 08. HEME OXYGENASE-1 INDUCTION INCREASES BILIARY BILE SALTS EXCRETION IN ETHINYLESTRADIOL-INDUCED CHOLESTASIS
Muchová L, Váňová K, Leníček M, Petr T, Mičuda S, Brčáková E, Fuksa L, Černý D, Farghali H, Wong R, Vreman H, Vítek L

C 09. CAFFEINE MAY BE PROTECTIVE IN ALCOHOLIC LIVER DAMAGE
Nikolic J, Acimovic D

C 10. HYPOGLYCEMIA IN ETHANOL TREATED RATS, IMPLICATION OF SERINE DEHYDRATASE ACTIVITY
Nikolic J, Acimovic D

C 11. EXPRESSION OF MITOCHONDRIA-RELATED GENES DURING LIVER REGENERATION IN A RAT AT 2/3 PARTIAL HEPATECTOMY MODEL EVALUATED BY DNA MICROARRAY ANALYSIS
Rychtrmoc D, Hubálková L, Víšková A, Libra A, Bunček M, Staňková P, Červinková Z

D. Viral Hepatitis

D 01. HEPATITIS B IN IRAQ: CRISIS AND RESCUE OPTIONS
Ali H, Ali F, Mohammed A

D 02. TRIAL OF LAMIVUDINE IN HEPATITIS B SURFACE ANTIGEN CARRIERS WITH PERSISTENCE HEPATITIS B CORE IgM ANTIBODY
Ali H, Ali F, Mohammed A

D 03. ASSOCIATION OF METABOLIC AND ULTRASOUND CHARACTERISTICS WITH HEPATITIS C GENOTYPE
Barbakdze G, Butsashvili M, Kamkamidze G

D 04. INTERFERON ALFA ANTIBODY (IFN ALFA Ab) As A USEFUL PREDICTIVE MARKER OF SUSTAINED VIRAL RESPONSE (SVR) FOR THERAPY IN CHRONIC HEPATITIS C
Basu P, Korapati R, Krishnaswamy NV, Shah NJ, Tang CC, Pacana T, Brown R

D 05. THE PATHOLOGICAL EVALUATION OF CHRONIC HEPATITIS C PATIENTS PRIOR TO ANTIVIRAL TREATMENT – A RETROSPECTIVE STUDY
Gologan E, Constantinescu R, Toader E, Plesa A, Mitrica D

D 06. THYROID HYPOFUNCTION A POSSIBLE IMPORTANT ETIOLOGY OF ANEMIA DURING INTERFERON THERAPY IN VIRUS C HEPATITIS
Helaly AZ

D 07. AUTOANTIBODIES AGAINST NOVEL CYTOPLASMIC STRUCTURES (RODS AND RINGS) ARE TIGHTLY ASSOCIATED WITH INTERFERON THERAPY IN HEPATITIS C PATIENTS
Keppeke G, Nunes E, Ferraz M, Granato C, Andrade L

D 08. NON-INVASIVE DIAGNOSTICS LIVER FIBROSIS AND HISTOLOGIC ACTIVITY INDEX IN PATIENTS WITH CHRONIC VIRAL HEPATITISES AT NORMAL LEVEL ALT
Pirogova IJ, Maevskaja MV, Pyshkin SA

D 09. HEPATIC STEATOSIS IN HEPATITIS C VIRUS INFECTION GENOTYPE 4 in EGYPT
Talaat A, Fatin A, Elsawy A

D 10. PHARMACOKINETICS AND SAFETY OF IVHEBEX® AN ANTI-HBS-ENRICHED IMMUNOGLOBULIN IN HEALTHY VOLUNTEERS AFTER INTRAVENOUS ADMINISTRATION
Tellier Z, Golly D, Grenot S, Andre MH